ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
AMAL Therapeutics Finalises €29 Million (CHF 33.2 Million) Series B Round
November 12, 2018The Company will use the funds to progress its lead vaccine (ATP128) toward clinical development and proof-of-concept in colorectal cancer, a leading cause of mortality and a significant market opportunity (€9.6 billion by 2025). The clinical trial is exp -
AMAL Therapeutics Finalises €29 Million (CHF 33.2 Million) Series B Round
November 12, 2018The Company will use the funds to progress its lead vaccine (ATP128) toward clinical development and proof-of-concept in colorectal cancer, a leading cause of mortality and a significant market opportunity (€9.6 billion by 2025). The clinical trial is exp
Pharma Sources Insight January 2025
